Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New agents for acute myelogenous leukemia.

J A Zwiebel1

  • 1Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.

Leukemia
|March 17, 2000
PubMed
Summary

New treatments for acute myelogenous leukemia (AML) show promise. These agents target histone acetylation, angiogenesis, and protein kinases, with efficacy and safety evaluated in early trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents.

Clinical pharmacology and therapeutics·2016
Same author

A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798).

Investigational new drugs·2007
Same author

Clinical trials referral resource. Current clinical trials of fenretinide.

Oncology (Williston Park, N.Y.)·2002
Same author

Endothelial cell-based systemic gene therapy of metastatic melanoma.

Cancer gene therapy·2001

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Acute myelogenous leukemia (AML) remains a significant challenge in hematologic malignancies.
  • Development of novel therapeutic agents with distinct mechanisms of action is crucial for improving patient outcomes.
  • Translating treatment strategies from solid tumors to hematologic disorders presents unique challenges.

Purpose of the Study:

  • To review emerging therapeutic agents for acute myelogenous leukemia.
  • To discuss novel treatment mechanisms including histone acetylation, angiogenesis inhibition, and protein kinase inhibition.
  • To evaluate the efficacy and safety of these agents in Phase I and II clinical trials.

Main Methods:

  • Review of Phase I and II clinical trial data for new AML therapeutic agents.
  • Analysis of treatment mechanisms: histone acetylation, angiogenesis inhibition, protein kinase inhibition, and novel retinoids.
  • Discussion of challenges in adapting solid tumor treatments for hematologic malignancies.

Main Results:

  • Several new agents targeting distinct pathways demonstrate potential in early-phase trials for AML.
  • Efficacy and safety profiles are being established for histone deacetylase inhibitors, anti-angiogenic agents, and protein kinase inhibitors.
  • A novel retinoid compound is also under investigation for its therapeutic effects.

Conclusions:

  • Novel therapeutic strategies targeting specific molecular pathways offer new hope for AML treatment.
  • Further research and clinical trials are necessary to confirm the efficacy and safety of these agents.
  • Addressing the complexities of transitioning treatments from solid tumors to blood cancers is essential for therapeutic advancement.

Related Experiment Videos